Following his opening keynote at this year’s Advanced Therapies Europe conference in Barcelona, Professor Jacob George, MHRA Chief Medical & Scientific Officer, explores the evolving regulatory landscape for advanced therapy medicinal products.
As biologic drug formats grow more sophisticated, scalable success depends on embedding manufacturability, analytics and quality thinking into molecular design from the very beginning of development.
Following her presentation at Advanced Therapies Europe, Charlotte Serra navigates the complexities of decentralised cell therapy manufacturing.
As chemotherapy use declines and targeted therapies assume a larger role in cancer treatment, researchers are looking beyond response rates to focus on real-world feasibility and reducing treatment burden for patients.
Applying the continuous-flow technology enabled domestication of previously uncultured bacteria, addressing a key bottleneck in laboratory microbial cultivation.
FDA’s latest approval authorises Bayer’s non-steroidal mineralocorticoid receptor antagonist (MRA) Kerendia for a third indication.
Divestment agreement expands decade-long collaboration between Sanofi and Cheplapharm, helps to hone Sanofi’s innovation focus.
The Danish pharmaceutical giant hopes the strategic rebranding and modernising its culture will sharpen the company’s competitive edge in the rapidly evolving obesity and diabetes therapeutics landscape.
In this webinar, FUJIFILM Wako Chemicals Europe GmbH will present the results of a study evaluating how NC stability in endotoxin detection reagents affects assay performance.
Pharmaceutical quality control laboratories face growing pressure to strengthen data integrity as regulators scrutinise incomplete records, manual data entry, and disconnected systems.
Following his opening keynote at this year’s Advanced Therapies Europe conference in Barcelona, Professor Jacob George, MHRA Chief Medical & Scientific Officer, explores the evolving regulatory landscape for advanced therapy medicinal products.
Following her presentation at Advanced Therapies Europe, Charlotte Serra navigates the complexities of decentralised cell therapy manufacturing.